

Appl. No. 10/694,978
Amdt. dated August 1, 2006

RECEIVED
CENTRAL FAX CENTER

AUG 01 2006

This listing of claims will replace all prior versions, and listings, of claims in our amendments or responses to Office actions. The following listing of claims reflects changes relative to Applicant's after-final amendment dated June 2, 2006.

Listing of Claims:

Claims 1-34. (Cancelled).

Claim 35. (Currently amended) An isolated or purified binding compound comprising an antigen binding site of an antibody that specifically binds to a polypeptide ~~having~~ consisting of the amino acid sequence of SEQ ID NO: 2 at an epitope comprising at least one sequence selected from the group consisting of:

FVHTSR (amino acids 45-50, SEQ ID NO: 2);
KKFSIHD (amino acids 58-64, SEQ ID NO: 2);
VLVLDS (amino acids 69-74, SEQ ID NO: 2);
NLIAVP (amino acids 76-81, SEQ ID NO: 2);
SLILLGV (amino acids 107-113, SEQ ID NO: 2); and
SRNMLES (amino acids 163-169, SEQ ID NO: 2).

Claim 36. (Currently amended) The binding compound of Claim 35, wherein the binding site of the antibody specifically binds to a polypeptide ~~having~~ consisting of the amino acid sequence of SEQ ID NO: 2 at an epitope comprising at least one sequence selected from the group consisting of:

KKFSIHD (amino acids 58-64, SEQ ID NO: 2);
VLVLDS (amino acids 69-74, SEQ ID NO: 2); and
NLIAVP (amino acids 76-81, SEQ ID NO: 2).

Claim 37. (Currently amended) An isolated or purified binding compound comprising an antigen binding site of an antibody that specifically binds to a polypeptide ~~having~~ consisting of the amino acid sequence of SEQ ID NO: 2 at an epitope comprising at least one sequence selected from the group consisting of:

SRKVKSLNPKKF (amino acids 49-60, SEQ ID NO: 2);

Atty.Dkt. DX0904KB1

Page 2 of 8

Appl. No. 10/694,978
Amdt. dated August 1, 2006

HDQDHKVLVLDS (amino acids 63-74, SEQ ID NO: 2);
NLIAVPDKNYIR (amino acids 76-87, SEQ ID NO: 2); and
FYRAQVGSRNML (amino acids 156-167, SEQ ID NO: 2).

Claim 38. (Currently amended) The binding compound of Claim 37, wherein the binding site of the antibody specifically binds to a polypeptide having consisting of the amino acid sequence of SEQ ID NO: 2 at an epitope comprising at least one sequence selected from the group consisting of:

SRKVKSLNPKKF (amino acids 49-60, SEQ ID NO: 2);
HDQDHKVLVLDS (amino acids 63-74, SEQ ID NO: 2); and
NLIAVPDKNYIR (amino acids 76-87, SEQ ID NO: 2).

Claim 39. (Previously presented) The binding compound of Claim 35, wherein the binding compound is a humanized antibody.

Claim 40. (Previously presented) The binding compound of Claim 37, wherein the binding compound is a humanized antibody.

Claim 41. (Previously presented) The binding compound of Claim 35, wherein the binding compound is an Fv, Fab, or F(ab')₂ fragment.

Claim 42. (Previously presented) The binding compound of Claim 37, wherein the binding compound is an Fv, Fab, or F(ab')₂ fragment.

Claim 43. (Previously presented) The binding compound of Claim 35, wherein the binding compound is glycosylated.

Claim 44. (Previously presented) The binding compound of Claims 37, wherein the binding compound is glycosylated.

Claim 45. (Previously presented) A binding composition comprising the binding compound of Claim 35, and a carrier, wherein the carrier is formulated for oral, rectal,

Atty.Dkt. DX0904KB1

Page 3 of 8

Appl. No. 10/694,978
Amdt. dated August 1, 2006

nasal, topical, parenteral, subcutaneous, intramuscular, intravenous, or intradermal administration.

Claim 46. (Previously presented) A binding composition comprising the binding compound of Claim 37, and a carrier, wherein the carrier is formulated for oral, rectal, nasal, topical, parenteral, subcutaneous, intramuscular, intravenous, or intradermal administration.

Claim 47. (Currently amended) A kit comprising:

- a) the binding compound of Claim 35;
- b) a compartment;
- b) instructions for use; and
- c) ~~the~~ a polypeptide ~~having~~ comprising the amino acid sequence of SEQ ID NO:

2.

Claim 48. (Currently amended) A kit comprising:

- a) the binding compound of Claim 37;
- b) a compartment;
- b) instructions for use; and
- c) ~~the~~ a polypeptide ~~having~~ comprising the amino acid sequence of SEQ ID NO:

2.

Claim 49. (Currently amended) A method of making the binding compound of Claim 35, comprising immunizing an animal with an immunogenic amount of a polypeptide having consisting of the amino acid sequence of SEQ ID NO: 2, or an antigenic fragment thereof.

Claim 50. (Currently amended) A method of making the binding compound of Claim 37, comprising immunizing an animal with an immunogenic amount of a polypeptide having consisting of the amino acid sequence of SEQ ID NO: 2, or an antigenic fragment thereof.

Appl. No. 10/694,978
Amdt. dated August 1, 2006

Claim 51. (Currently amended) A method of producing an antigen:antibody complex, comprising contacting a polypeptide ~~having~~ comprising the amino acid sequence of SEQ ID NO: 2 with the antibody of Claim 35 and allowing a complex to form.

Claim 52. (Currently amended) A method of producing an antigen:antibody complex, comprising contacting a polypeptide ~~having~~ comprising the amino acid sequence of SEQ ID NO: 2 with the antibody of Claim 37 and allowing a complex to form.

Claim 53. (Currently amended) An isolated or purified binding compound comprising an antigen binding site of an antibody that specifically binds to a polypeptide ~~having~~ consisting of the amino acid sequence of SEQ ID NO: 2 at an epitope found within amino acids 49-89 of SEQ ID NO: 2.